Incyte (NASDAQ:INCY) has announced new data from the Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura®) in children with atopic dermatitis (AD). The study met its primary endpoint with significantly more patients treated with ruxolitinib cream achieving Investigator's Global Assessment Treatment Success (IGA-TS) than patients treated with vehicle control. The cream was well tolerated with no serious infections, major adverse cardiovascular events, malignancies or thromboses reported during the 8-week vehicle-controlled period.